$95M Settlement Reached in Amgen Securities Class Action Lawsuit

This is a settlement for the Amgen Inc. lawsuit.

- by

Santa Clara, CA: A $95 million settlement has been reached in a securities class action lawsuit pending against pharmaceutical company Amgen Inc.

Brought by investors, the suit claims that Amgen failed to disclose the results of a study known as DAHANCA 10, which tested Aranesp in head and neck cancer patients in Denmark. When Amgen’s failure to disclose was discovered and reported, the company’s stock crashed.

The period in which class members were affected is between April 22, 2004 and May 10, 2007. Under the agreement, Amgen will pay $95 million into a settlement fund to be distributed to class members. The settlement is subject to court approval.

The lawsuit is In re Amgen Inc. Securities Litigation, CV-07-2536 PSG, pending in the United States District Court for the Central District of California.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form on the right.

Add Your Comment on This Issue

Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Request Legal Help